SynthesisEuropean journal of pediatrics2019
Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials.
Synthesis in European journal of pediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 5 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- Probiotics for pediatric diarrhea and constipation: an umbrella meta-analysis.BMC pediatrics · 2025Pooled it
- The effect of probiotics on the diarrhea and constipation outcomes in children: an umbrella review of systematic reviews and meta-analyses.Frontiers in nutrition · 2025Pooled it
- Efficacy and safety of bifidobacterium quadruple viable tablets in the treatment of Helicobacter pylori-infected peptic ulcer or gastritis patients: a systematic review and meta-analysis.BMC infectious diseases · 2023Pooled it
- Use of probiotics in the treatment of functional abdominal pain in children-systematic review and meta-analysis.European journal of pediatrics · 2021Pooled it
- Efficacy of Lactobacillus-supplemented triple therapy for H. pylori eradication: A meta-analysis of randomized controlled trials.PloS one · 2019Pooled it
- Metagenomic Changes of Gut Microbiota following Treatment ofNutrients · 2022Trial
- Intelligent Algorithm-Based Gastrointestinal X-Ray Examination in Evaluating the Therapeutic Effect of Probiotics Combined with Triple Therapy on Children withContrast media & molecular imaging · 2022Trial
- Article
- Food as Friend or Foe: A Decadal Narrative Review of Dietary Patterns as Determinants of Gastrointestinal Pathophysiology and Clinical Outcomes (2015-2025).International journal of molecular sciences · 2026Review
- The therapeutic potential ofFrontiers in microbiology · 2026Review
- Potassium-competitive acid blockers forFrontiers in cellular and infection microbiology · 2026Review
- Effects of Lactobacillus spp. on Helicobacter pylori: A Promising Frontier in the Era of Antibiotic Resistance.Probiotics and antimicrobial proteins · 2025Review
- Probiotics as Adjuvants to StandardMicroorganisms · 2025Review
- Global Profile of Drug Resistance Related toHealth science reports · 2025Review
- Article
- Antimicrobial Activity of Probiotic Bacteria Isolated from Plants: A Review.Foods (Basel, Switzerland) · 2025Review
- The Impact of Bioactive Molecules from Probiotics on Child Health: A Comprehensive Review.Nutrients · 2024Review
- Research Progress for Probiotics Regulating Intestinal Flora to Improve Functional Dyspepsia: A Review.Foods (Basel, Switzerland) · 2024Review
- Role of Probiotics in the Treatment and Prevention of Common Gastrointestinal Conditions in Children.Pediatric gastroenterology, hepatology & nutrition · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapy-related side effects and severe antimicrobial resistance still remain an obstacle to Helicobacter pylori eradication. This meta-analysis aimed to investigate the efficacy of Lactobacillus-supplemented triple therapy on H. pylori eradication rates and therapy-related side effects in children. Five studies involving 484 pediatric patients were included in our analysis. The pooled relative risk (RR) for eradication rates in the Lactobacillus group versus the control group was 1.19 [95% confidence interval (CI) 1.07-1.33]. In subgroup analyses based on dose and duration of Lactobacillus supplementation, the pooled RRs for eradication rates were 1.36 (95% CI 1.15-1.60) in the high-dose group, 1.08 (95% CI 0.86-1.35) in the low-dose group, 1.24 (95% CI 1.06-1.46) in the long-term group, and 1.17 (95% CI 0.96-1.44) in the short-term group. With respect to side effects, Lactobacillus supplementation significantly reduced the incidence of diarrhea (RR = 0.30, 95% CI 0.10-0.85).Conclusions: Lactobacillus, as an adjunct to triple therapy, can increase H. pylori eradication rates as well as reduce the incidence of therapy-related diarrhea in children. And a higher dose and a longer duration of supplementation may conduce to the positive impact of Lactobacillus on H. pylori eradication. What is Known: • Probiotics-supplemented triple therapy may be beneficial in improving H. pylori eradication rates and reducing therapy-related side effects in children. However, not all probiotics are beneficial to H. pylori eradication and the pooled outcomes based on different probiotics may be erroneously extrapolated to other ineffective strains. What is New: • Lactobacillus, as an adjunct to triple therapy, can increase H. pylori eradication rates as well as reduce the incidence of therapy-related diarrhea in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.